Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.

"Guarantor of the article: David C. Metz, MD.: Specific author contributions: Initiated the study concept and design, analysis, and interpretation of data, critical revision of the paper: David C. Metz; study design, analysis, and interpretation of data; critical revision of the paper: Betsy L. Pilmer; study design, conducted the data analysis, and critical revision of the paper: Cong Han; study design, analysis and interpretation; critical revision of the paper: M. Claudia Perez. All authors have seen and approved the final report.: Financial support: This analysis was sponsored by Takeda Global Research & Development Center.: Potential competing interests: D.C. Metz has served as a consultant and reports receiving honoraria and/or grant support from AstraZeneca, Takeda, Novartis Consumer, and Xenoport. B.L. Pilmer, C. Han, and M.C. Perez are employees of Takeda Global Research & Development Center, Deerfield, IL, USA."

"Financial support: This analysis was sponsored by Takeda Global Research & Development Center."